A Trial for Patients With Advanced/Recurrent Endometrial Cancer

Inclusion Criteria

• •Patients must have recurrent or persistent endometrial adenocarcinoma, which is refractory to curative therapy or established treatments.
• •Patients must have measurable disease.
• •Patients must have had one prior chemotherapeutic regimen for management of endometrial carcinoma.
• •Patients must have signed an approved informed consent.
• •Patients of childbearing potential must have a negative serum pregnancy test prior to the study entry and be practicing an effective form of contraception during the study and for at least 3 months following the last dose of Pemetrexed.
• •Patients must discontinue nonsteroidal anti-inflammatory (NSAIDs) medications 2-5 days prior to and for 1-2 days after receiving Pemetrexed, depending on the half-life of the NSAIDs treatment.
• •Patients must agree to this schedule in conjunction with every dose of Pemetrexed.
• •Patients must receive 350-1000 mcg of folic acid (e.g. one prenatal vitamin) starting 7 days prior to the first treatment with Pemetrexed.
• •Patients must be able to ingest 350-1000 mcg of folic acid daily until 3 weeks after the last dose of Pemetrexed.
• •Patients must receive 4 mg Dexamethasone by mouth twice daily, 1 day prior to the dose, the day of and the day after every dose of Pemetrexed.
• •Patients must receive a 1000 mcg vitamin B12 injection 7 days prior to receiving the first treatment with Pemetrexed.
• •Patients must agree to receive 1000 mcg vitamin B12 injection every 9 weeks until 3 weeks after the last dose of Pemetrexed.